{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000012","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.613447+00:00","generated_at":"2026-05-15T22:47:17.802560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M","bullets":["Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.","Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).","FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.","Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.","Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000012","json":"https://secwatch.observer/filing/0001867096-26-000012.json","markdown":"https://secwatch.observer/filing/0001867096-26-000012.md","text":"https://secwatch.observer/filing/0001867096-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/0001867096-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/xers-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:47:17.802560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}